Search Results - "Sullivan, James C."

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials by Sullivan, James C., De Meyer, Sandra, Bartels, Doug J., Dierynck, Inge, Zhang, Eileen Z., Spanks, Joan, Tigges, Ann M., Ghys, Anne, Dorrian, Jennifer, Adda, Nathalie, Martin, Emily C., Beumont, Maria, Jacobson, Ira M., Sherman, Kenneth E., Zeuzem, Stefan, Picchio, Gaston, Kieffer, Tara L.

“…Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact…”
Get full text

Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment by Bartels, Doug J, Sullivan, James C, Zhang, Eileen Z, Tigges, Ann M, Dorrian, Jennifer L, De Meyer, Sandra, Takemoto, Darin, Dondero, Elizabeth, Kwong, Ann D, Picchio, Gaston, Kieffer, Tara L

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials by Kieffer, Tara L, De Meyer, Sandra, Bartels, Doug J, Sullivan, James C, Zhang, Eileen Z, Tigges, Ann, Dierynck, Inge, Spanks, Joan, Dorrian, Jennifer, Jiang, Min, Adiwijaya, Bambang, Ghys, Anne, Beumont, Maria, Kauffman, Robert S, Adda, Nathalie, Jacobson, Ira M, Sherman, Kenneth E, Zeuzem, Stefan, Kwong, Ann D, Picchio, Gaston

“…In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased…”
Get full text

G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect by Fidler, Meredith C., Buckley, Alexandra, Sullivan, James C., Statia, Marvin, Boj, Sylvia F., Vries, Robert G. J., Munck, Anne, Higgins, Mark, Moretto Zita, Matteo, Negulescu, Paul, Goor, Fredrick, De Boeck, Kris

“…In previous work, participants with a G970R mutation in cystic fibrosis transmembrane conductance regulator (CFTR) (c.2908G>C) had numerically lower sweat…”
Get full text

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3-4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study by Dierynck, Inge, Thys, Kim, Ghys, Anne, Sullivan, James C., Kieffer, Tara L., Aerssens, Jeroen, Picchio, Gaston, De Meyer, Sandra

“…Background. Population sequencing (PS) has shown that telaprevir-resistant variants are not typically detectable at baseline (prevalence, ≤5% of patients), and…”
Get full text

Targeted quantitation of CFTR protein expression in vivo using immunoprecipitation & parallel reaction monitoring tandem mass spectrometry by Wang, Hui, Dai, Yunxiang, Clark, Nicholas, Boeglin, Lianne, Woo, Caroline, Wooster, Richard, Sun, Gang, Sullivan, James C.

“…Abstract Background The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a low-abundance membrane protein. The dysfunction of CFTR protein…”
Get full text

Rising starlet: the starlet sea anemone, Nematostella vectensis by Darling, John A., Reitzel, Adam R., Burton, Patrick M., Mazza, Maureen E., Ryan, Joseph F., Sullivan, James C., Finnerty, John R.

“…In recent years, a handful of model systems from the basal metazoan phylum Cnidaria have emerged to challenge long‐held views on the evolution of animal…”
Get full text

Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir by Thomas, Xiomara V, de Bruijne, Joep, Sullivan, James C, Kieffer, Tara L, Ho, Cynthia K Y, Rebers, Sjoerd P, de Vries, Michel, Reesink, Hendrik W, Weegink, Christine J, Molenkamp, Richard, Schinkel, Janke

“…Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated…”
Get full text

The evolutionary origin of the Runx/CBFbeta transcription factors--studies of the most basal metazoans by Sullivan, James C, Sher, Daniel, Eisenstein, Miriam, Shigesada, Katsuya, Reitzel, Adam M, Marlow, Heather, Levanon, Ditsa, Groner, Yoram, Finnerty, John R, Gat, Uri

“…Members of the Runx family of transcriptional regulators, which bind DNA as heterodimers with CBFbeta, are known to play critical roles in embryonic…”
Get full text

Modeling viral evolutionary dynamics after telaprevir-based treatment by Haseltine, Eric L, De Meyer, Sandra, Dierynck, Inge, Bartels, Doug J, Ghys, Anne, Davis, Andrew, Zhang, Eileen Z, Tigges, Ann M, Spanks, Joan, Picchio, Gaston, Kieffer, Tara L, Sullivan, James C

“…For patients infected with hepatitis C virus (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and…”
Get full text

Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis by Sullivan, James C, Kalaitzidis, Demetrios, Gilmore, Thomas D, Finnerty, John R

“…The Rel/NF-kappaB and NFAT families of transcription factors are related through an N-terminal DNA-binding domain called the Rel Homology domain (RHD). Neither…”
Get full text

Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia by Woo, Caroline J., Allawzi, Ayed, Clark, Nicholas, Kaushal, Neha, Efthymiou, Tim, Thamsen, Maike, Nguyen, Jane, Wooster, Richard, Sullivan, James C.

“…Primary ciliary dyskinesia (PCD) is a respiratory disease caused by dysfunction of the cilia with currently no approved treatments. This predominantly…”
Get full text

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment by Sullivan, James C, Zhang, Eileen Z, Bartels, Doug J, Tigges, Ann, Dorrian, Jennifer L, Kwong, Ann D, Kieffer, Tara L

“…Development of compensatory mutations within the HIV p7/p1 and p1/p6 protease cleavage site region has been observed in HIV-infected patients treated with…”
Get full text

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial by De Meyer, Sandra, Dierynck, Inge, Ghys, Anne, Beumont, Maria, Daems, Bjorn, Van Baelen, Ben, Sullivan, James C., Bartels, Douglas J., Kieffer, Tara L., Zeuzem, Stefan, Picchio, Gaston

“…In the Phase 3 REALIZE study, 662 genotype 1 hepatitis C virus (HCV)‐infected patients with prior peginterferon/ribavirin treatment failure (including…”
Get full text

Qualitative shift to indirect development in the parasitic sea anemone Edwardsiella lineata by Reitzel, Adam M., Sullivan, James C., Finnerty, John R.

“…Direct development lies at 1 end of a continuum that encompasses various degrees of indirect development. Indirect development exists where a larval stage is…”
Get full text

A High Percentage of Introns in Human Genes Were Present Early in Animal Evolution: Evidence from the Basal Metazoan Nematostella vectensis by Sullivan, James C., Reitzel, Adam M., Finnerty, John R.

“…Intronic sequences represent a large fraction of most eukaryotic genomes, and they are knownto play a critical role in genome evolution. Based on the conserved…”
Get full text

Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C → T or D1152H Residual Function Mutation by Kerem, Eitan, Cohen-Cymberknoh, Malena, Tsabari, Reuven, Wilschanski, Michael, Reiter, Joel, Shoseyov, David, Gileles-Hillel, Alex, Pugatsch, Thea, Davies, Jane C, Short, Christopher, Saunders, Clare, DeSouza, Cynthia, Sullivan, James C, Doyle, Jamie R, Chandarana, Keval, Kinnman, Nils

“…Ivacaftor's clinical effects in the residual function mutations and warrant further characterization. To evaluate ivacaftor's effect in people with cystic…”
Get full text

Concerted Evolution of Sea Anemone Neurotoxin Genes Is Revealed through Analysis of the Nematostella vectensis Genome by Moran, Yehu, Weinberger, Hagar, Sullivan, James C., Reitzel, Adam M., Finnerty, John R., Gurevitz, Michael

“…Gene families, which encode toxins, are found in many poisonous animals, yet there is limited understanding of their evolution at the nucleotide level. The…”
Get full text

Telaprevir‐based treatment effects on hepatitis C virus in liver and blood by Talal, Andrew H., Dimova, Rositsa B., Zhang, Eileen Z., Jiang, Min, Penney, Marina S., Sullivan, James C., Botfield, Martyn C., Chakilam, Ananthsrinivas, Sawant, Rishikesh, Cervini, Christine M., Zeremski, Marija, Jacobson, Ira M., Kwong, Ann D.

“…Understanding hepatitis C virus (HCV) replication has been limited by access to serial samples of liver, the primary site of viral replication. Our…”
Get full text

Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor by Jiang, Min, Zhang, Eileen Z, Ardzinski, Andrzej, Tigges, Ann, Davis, Andrew, Sullivan, James C, Nelson, Michelle, Spanks, Joan, Dorrian, Jennifer, Nicolas, Olivier, Bartels, Doug J, Rao, B Govinda, Rijnbrand, Rene, Kieffer, Tara L

“…VX-222, a thiophene-2-carboxylic acid derivative, is a selective nonnucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. In…”
Get full text